Boston Scientific Corporation $BSX Holdings Raised by Welch Group LLC

Welch Group LLC raised its holdings in shares of Boston Scientific Corporation (NYSE:BSX) by 3.5% in the 2nd quarter, Holdings Channel reports. The firm owned 4,641 shares of the medical equipment provider’s stock after purchasing an additional 159 shares during the quarter. Welch Group LLC’s holdings in Boston Scientific were worth $498,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. Brighton Jones LLC grew its position in shares of Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock valued at $2,445,000 after buying an additional 226 shares during the last quarter. Wealthcare Advisory Partners LLC grew its holdings in shares of Boston Scientific by 25.8% during the first quarter. Wealthcare Advisory Partners LLC now owns 3,675 shares of the medical equipment provider’s stock valued at $371,000 after purchasing an additional 754 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Boston Scientific by 17.2% during the first quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider’s stock valued at $2,578,000 after purchasing an additional 3,745 shares during the last quarter. CVA Family Office LLC grew its holdings in shares of Boston Scientific by 10.2% during the first quarter. CVA Family Office LLC now owns 2,668 shares of the medical equipment provider’s stock valued at $269,000 after purchasing an additional 247 shares during the last quarter. Finally, Azzad Asset Management Inc. ADV bought a new position in shares of Boston Scientific during the first quarter valued at approximately $2,267,000. Institutional investors own 89.07% of the company’s stock.

Insider Activity at Boston Scientific

In other news, Director Edward J. Ludwig sold 4,000 shares of the stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total value of $424,120.00. Following the completion of the transaction, the director directly owned 18,479 shares in the company, valued at $1,959,328.37. This trade represents a 17.79% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 174,214 shares of company stock valued at $17,972,457. Insiders own 0.50% of the company’s stock.

Boston Scientific Trading Down 1.9%

NYSE:BSX opened at $95.41 on Monday. Boston Scientific Corporation has a 1 year low of $80.64 and a 1 year high of $109.50. The stock has a market cap of $141.38 billion, a price-to-earnings ratio of 56.79, a PEG ratio of 2.30 and a beta of 0.61. The business has a fifty day moving average of $101.98 and a 200-day moving average of $101.87. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX) last announced its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. The firm had revenue of $5.06 billion during the quarter, compared to analyst estimates of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific’s revenue was up 22.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Equities analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analyst Weigh In

BSX has been the subject of a number of recent research reports. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a research note on Monday, June 16th. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $118.00 to $125.00 in a research note on Monday, September 8th. Wells Fargo & Company upped their price target on shares of Boston Scientific from $118.00 to $124.00 and gave the stock an “overweight” rating in a research report on Thursday, July 24th. Robert W. Baird upped their price target on shares of Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Truist Financial upped their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the stock a “buy” rating in a research report on Wednesday, October 1st. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Boston Scientific has an average rating of “Buy” and a consensus target price of $120.71.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.